Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 11/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 9/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 6/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.37 |
| ▸ | L3MBTL4 | Q8NA19 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8263855 | 0.98 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1HRH3CYP2D6 | |
| SCHEMBL278657 | 0.98 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1HRH3CYP2D6 | |
| SCHEMBL8255448 | 0.98 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1MBTD1HRH3CYP2D6 | |
| SCHEMBL8259607 | 0.96 | L3MBTL3 (0.46) | L3MBTL3L3MBTL1MBTD1HRH3CYP2D6 | |
| SCHEMBL10162401 | 0.95 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL25050072 | 0.94 | L3MBTL3 (0.44) | L3MBTL3L3MBTL1MBTD1HRH3TP53BP1 | |
| SCHEMBL10162384 | 0.92 | HRH3 (0.46) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL22456360 | 0.91 | L3MBTL3 (0.42) | L3MBTL3L3MBTL1MBTD1HRH3CYP2D6 | |
| SCHEMBL10162381 | 0.89 | HRH3 (0.43) | L3MBTL3L3MBTL1MBTD1HRH3 | |
| SCHEMBL22456382 | 0.88 | HRH3 (0.49) | L3MBTL3L3MBTL1MBTD1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 243 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-06-27 | — | — | US | disclosed |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2024-06-27 | — | — | US | disclosed |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | INVENTISBIO CO LTD (CN) | 2024-06-27 | — | — | US | disclosed |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | SAREPTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| WO-2023247595-A1 | PYRAZOLOPYRAZINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247590-A1 | TRIAZOLOPYRIDINE AND BENZOISOXAZOLE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| WO-2023247593-A1 | PYRROLOPYRIDINE CARBOXAMIDES AND THEIR USES AS PDGFR INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2023-12-28 | — | — | WO | disclosed |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | SHENZHEN NEWDEL BIOTECH CO., LTD. (CN) | 2023-12-05 | — | — | US | disclosed |
| US-7208602-B2 | Gamma secretase inhibitors | SCHERING CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2007-03-01 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-11 | — | — | US | disclosed |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-7157420-B2 | Therapeutic agents and methods of use thereof for the modulation of angiogenesis | PRAECIS PHARMACEUTICALS, INC. (US) | 2007-01-02 | — | — | US | disclosed |
| US-20050085506-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION AND PHARMACOPEIA, INC. | 2005-04-21 | — | — | US | disclosed |
| US-20040229902-A1 | Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors | SCHERING CORPORATION | 2004-11-18 | — | — | US | disclosed |
| US-20040171614-A1 | Novel gamma secretase inhibitors | SCHERING-PLOUGH CORPORATION | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010452-A1 | Methionine aminopeptidase-2 inhibitors and methods of use thereof | METAP2, METAP1, DNPEP | L3MBTL3 515/4885L3MBTL1 456/4885MBTD1 1889/4885 |
| US-20040171614-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | L3MBTL3 3906/4885L3MBTL1 4015/4885MBTD1 4148/4885 |
| US-20240209363-A1 | OLIGONUCLEOTIDES FOR TREATING EXPANDED REPEAT DISEASES | HTT, UPF1, TARDBP | L3MBTL3 87/4885L3MBTL1 112/4885MBTD1 1690/4885 |
| US-20240208967-A1 | Pyrimidine or Pyridine Compounds, Preparation Method Therefor and Pharmaceutical Uses Thereof | EGFR, WEE1, DPYD | L3MBTL3 2963/4885L3MBTL1 1959/4885MBTD1 4215/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | L3MBTL3 2681/4885L3MBTL1 1477/4885MBTD1 2242/4885 |
| US-20070049555-A1 | Indenoisoquinolinone analogs and methods of use thereof | TNNI3, IDH2, GLS | L3MBTL3 2147/4885L3MBTL1 2667/4885MBTD1 2952/4885 |
| US-11834454-B2 | Alkynylphenylbenzamide compounds and applications thereof | ALK, NTRK1, ERBB2 | L3MBTL3 1943/4885L3MBTL1 2746/4885MBTD1 3003/4885 |
| US-20070004764-A1 | Nitrogen-containing aromatic derivatives | NR0B2, NR0B1, NR4A1 | L3MBTL3 2896/4885L3MBTL1 2633/4885MBTD1 3942/4885 |
| US-20050085506-A1 | Novel gamma secretase inhibitors | BACE1, BACE2, APP | L3MBTL3 2301/4885L3MBTL1 2500/4885MBTD1 3916/4885 |
| US-11911403-B2 | Antisense-induced exon exclusion in type VII collagen | COL2A1, COL14A1, COL1A1 | L3MBTL3 626/4885L3MBTL1 304/4885MBTD1 2489/4885 |
| US-20040229902-A1 | Bridged N-arylsulfonylpiperidines as gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | L3MBTL3 4609/4885L3MBTL1 4095/4885MBTD1 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.